The Society for Cardiovascular Angiography & Interventions (SCAI) is pleased to announce the publication of the Expert ...

CCCTN registry data reinforce the message that DanGer Shock’s findings supporting MCS apply narrowly to patients studied.

A study of over 450,000 NSTEMI admissions reveals that diabetics face disparities in care, with less invasive treatment ...

The experts provide a how-to on dealing with sticky situations, such as no-flow and large thrombus, during PCI for STEMI.

The Society for Cardiovascular Angiography & Interventions (SCAI) is pleased to announce the publication of the Expert Consensus Statement on the Management of Patients with STEMI Referred for Primary ...

The following is a summary of "Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results," published in the October 2024 issue of Cardiology by Stone et al. In the ...

The following is a summary of “Role of Inflammation in Early Left Ventricular Thrombus Formation Following ST-Elevation Myocardial Infarction—A Matched Case-Control Study,” published in the October ...

"By providing these consensus key points, we are not only helping to ensure consistency in treatment approaches but also aiming to improve the overall quality of care for STEMI patients globally.

Myocardial Infarction, Cardiovascular Disease, Prevention, Challenges, Review Abdin, A. (2024) Myocardial Infarction and the Prevention Strategies Keeping it at Bay: A Narrative Review. Open Access ...

The Global Myocardial Infarction Therapeutics Market is estimated to be valued at USD 15.56 billion in 2023 and is projected to grow at a CAGR of 4.19% over the forecast period 2024-2032. Read the ...

ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug ...

In patients with axial spondyloarthritis and a history of cardiovascular events, recurrent cardiovascular events were ...